Baby Cough Syrup Case: The four syrups “have been possibly connected with acute renal damage and 66 fatalities among children,” according to Tedros Adhanom Ghebreyesus, the director of the WHO in the Gambia.
Baby Cough Syrup Case: The World Health Organization (WHO) issued a warning that four cough syrups produced by a pharmaceutical company in Haryana may have contributed to the deaths of 66 children in The Gambia, prompting the government to launch an inquiry.
The WHO allegedly informed the Drugs Controller General of India (DCGI) about the cough syrups on September 29 according to reputable sources within the Ministry of Health and Family Welfare. The sources claim that the Central Drugs Standard Control Organization immediately raised the matter with the Haryana regulatory agency and launched a thorough investigation.
Sources claim that M/s Maiden Pharmaceutical Limited manufactures cough medicines in Sonepat, Haryana. They went on to state that it appears from the available data. That the corporation has only exported these commodities to The Gambia. The company has not yet reacted to the charges. The company’s administrative office in Pitampura, Delhi, was shut down this morning.
…
The WHO has issued a warning that a worldwide exposure. Is “probable” and that the syrups may have been disseminate outside of the West African nation.
The four cold and cough medications “have been possibly related with acute kidney impairment and 66 child fatalities,” said Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, addressing reporters yesterday.
WHO has not yet published the “exact one to one causation relationship of mortality,” according to ministry sources. Additionally, they mentioned that the WHO has not yet made information. And pictures of labels attesting to the producers of the products available.
Baby Cough Syrup Case: The exact date that these fatalities occurr has not yet been disclose by the WHO.
According to reports, samples of the four cough syrups. Will now be analyze at national and local laboratories, with findings arriving in two days. According to the sources, any medicine exported from India is subject to recipient nation testing as per protocol. The issue, according to the sources, is why the contamination was not found during testing in The Gambia. They said that the WHO has not disclose if the medications had been use unteste in the west African nation.
…
According to the WHO recommendation. The four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup.
Laboratory analysis of product samples, according to the warning. “Confirms that they include excessive concentrations of diethylene glycol and ethylene glycol as impurities”. And “to far, the stated producer has not supplied assurances to WHO on the safety and quality of these items.”
It said that the harmful effects “may include stomach discomfort, vomiting, diarrhoea, difficulty to pass urine, headache, changed mental state, and severe renal damage which may lead to death” as a result of exposure to such drugs.
[…] Baby Cough Syrup Case: Following a WHO alert on 66 child deaths, India investigates four cough syrup… […]